Logic-Gated HSV-TK/GCV Suicide Gene Circuit for Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Gene Therapy
• Molecular Biology

Background:

• Triple-negative breast cancer (TNBC) presents significant clinical challenges due to its complexity, resistance to therapies, and lack of targeted treatments.
• The herpes simplex virus thymidine kinase/ganciclovir (HSV-TK/GCV) suicide gene therapy system offers potential but is limited by off-target toxicity.

Purpose of the Study:

• To develop a precise and specific suicide gene circuit for targeting triple-negative breast cancer.
• To overcome the off-target cytotoxicity associated with traditional HSV-TK/GCV therapy.

Main Methods:

• Engineered a breast cancer-specific suicide gene circuit (BRAS) integrating cancer-specific promoters (RRM2, MAFK) and a non-tumor cell-specific microRNA.
• Utilized a multi-input logic gate design for precise regulation of HSV-TK expression.
• Tested BRAS in patient-derived TNBC cells and orthotopic breast cancer models.

Main Results:

• BRAS demonstrated highly specific expression of HSV-TK in breast cancer cells with minimal expression in normal cells.
• Selective induction of apoptosis in patient-derived TNBC cells was observed, while normal cells remained unaffected.
• Significant suppression of tumor growth in orthotopic models without adverse effects on animal health.

Conclusions:

• The developed BRAS system offers a promising strategy for targeted triple-negative breast cancer therapy.
• This approach intelligently combines tumor and normal cell molecular signals for precise therapeutic gene expression regulation.
• BRAS represents a potential platform for next-generation cancer therapeutics with improved specificity and reduced toxicity.